RELOXIFENE

Raloxifene prevents and treats osteoporosis by mimicking the effects of the female hormone estrogen. It does this by increase the density or thickness of bone, osteoporosis in postmenopausal women and those on glucocorticoids. It is also used to reduce the risk of breast cancer in those at high risk of developing invasive breast cancer because it blocks the effects of estrogen on breast tissue. Raloxifene acts as an estrogen agonist in bone reducing resorption of bone and increases bone mineral density in postmenopausal women, however, Raloxifine does it without stimulating the endometrium or breast tissue. It decreases the circulation of estrogen after oophorectomy or menopause leading to enhanced bone resorption. Raloxifene is sold under the brand name Evista, Optruma, Keoxifene; Pharoxifene among others. Eli Lilly and Company was given approval for medical use of Raloxifene in the United States in 1997. With more than a million subscriptions in the USA alone, is now sold as a generic medication manufactured under several brand names.

Dosage and administration

Raloxifene is sold as tablets. The recommended Usual Adult Dose for treatment and prevention of Osteoporosis is 60 mg orally per day. The dose for Prevention of Breast Cancer is also set at 60 mg per day, taken orally.

The Price of Raloxifene

The price of this drug varies by brand and generic formulation around the world. The consumers have to pay an average retail price of USD 1.8 for a supply of 10 tablets of 60mg. In the UK, the consumer has to pay £3.81 for a supply of 20 tablets of 28 mg.

How does Raloxifene work?

Raloxifene is an estrogen agonist/antagonist, also known as a selective estrogen receptor modulator. The actions of Raloxifene are mediated through binding to estrogen receptors. This activates estrogenic pathways in some tissues (agonism) leading to a blockade of estrogenic pathways in others (antagonism). If it acts as agonistic or antagonistic action depends on the recruitment of coactivators and corepressors to estrogen receptor target gene promotors. Raloxifene is an estrogen agonist in bone, which decreases bone resorption and bone turnover, thus increasing bone mineral density and decreases the incidence of fracture. Raloxifene is an estrogen antagonist in uterine and breast tissues but lacks estrogen-like effects on the uterus and breast tissue.

Finding Reloxifene Manufacturers and Suppliers

The best way to find and gain access to Reloxifene manufacturers and Reloxifene suppliers is to make through Pipelinepharma's global B2B online marketplace for medicines and other pharmaceuticals. Normally, finding trusted manufacturers and supplies of specific drugs like Reloxifene can be a time- consuming challenge, but with Pipelinepharma's simple search engine and network of proven partners, the whole process becomes a lot easier. All you need to do to get started is to make use of our integrated search engine and start looking for suppliers or manufacturers of Reloxifene to work with. You can fine-tune your search results using various filters too, letting you search for Reloxifene from specific countries.